DNA Damage Repair Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">DNA Damage Repair Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside (NR)</td>
<td>NAD+ precursor</td>
</tr>
<tr>
<td class="label">PARP inhibitors (various)</td>
<td>PARP1/2</td>
</tr>
<tr>
<td class="label">ATM inhibitors</td>
<td>ATM kinase</td>
</tr>
</table>
Overview
DNA damage repair therapy represents an emerging therapeutic strategy for neurodegenerative diseases based on the understanding that accumulated DNA damage in [neurons](/entities/neurons) contributes to aging-related neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@hedskog2023][@madabhushi2014]. The central nervous system faces constant oxidative stress from mitochondrial metabolism, and neurons' post-mitotic state means they cannot dilute damage through cell division, making DNA repair mechanisms critically important[@di2009].
This therapy approach aims to enhance endogenous DNA repair capacity, reduce DNA damage accumulation, and protect neuronal function through multiple mechanisms including base excision repair (BER), nucleotide excision repair (NER), and ATM/ATR signaling pathway modulation[@caldecott2007][@maynard2015].
Mechanism of Action
Base Excision Repair (BER)
...DNA Damage Repair Therapy
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">DNA Damage Repair Therapy for Neurodegeneration</th>
</tr>
<tr>
<td class="label">Agent</td>
<td>Target</td>
</tr>
<tr>
<td class="label">Nicotinamide riboside (NR)</td>
<td>NAD+ precursor</td>
</tr>
<tr>
<td class="label">PARP inhibitors (various)</td>
<td>PARP1/2</td>
</tr>
<tr>
<td class="label">ATM inhibitors</td>
<td>ATM kinase</td>
</tr>
</table>
Overview
DNA damage repair therapy represents an emerging therapeutic strategy for neurodegenerative diseases based on the understanding that accumulated DNA damage in [neurons](/entities/neurons) contributes to aging-related neurodegeneration in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS)[@hedskog2023][@madabhushi2014]. The central nervous system faces constant oxidative stress from mitochondrial metabolism, and neurons' post-mitotic state means they cannot dilute damage through cell division, making DNA repair mechanisms critically important[@di2009].
This therapy approach aims to enhance endogenous DNA repair capacity, reduce DNA damage accumulation, and protect neuronal function through multiple mechanisms including base excision repair (BER), nucleotide excision repair (NER), and ATM/ATR signaling pathway modulation[@caldecott2007][@maynard2015].
Mechanism of Action
Base Excision Repair (BER)
BER is the primary pathway for repairing small, non-helix-distorting base lesions caused by oxidative damage and alkylation[@david2007]. Key enzymes in this pathway include:
- Poly(ADP-ribose) polymerases (PARPs): PARP1 and PARP2 detect single-strand breaks and initiate BER by synthesizing poly(ADP-ribose) chains as a recruitment signal for repair proteins[@gibson2012]
- DNA glycosylases: OGG1 removes 8-oxoguanine (8-oxoG), while NEIL1 and NEIL2 process other oxidative lesions[@krokan2013]
- AP endonucleases: APEX1 cleaves abasic sites generated by glycosylase action[@tell2012]
- DNA polymerases: POLβ performs gap-filling synthesis[@beard2014]
Therapeutic strategies include PARP inhibitors to prevent excessive PARP activation that can lead to cell death, and agents that enhance glycosylase expression[@ame2004].
Nucleotide Excision Repair (NER)
NER removes bulky helix-distorting lesions including UV-induced photoproducts and environmental carcinogen adducts[@gillet2006]. Two NER sub-pathways exist:
- Global Genome NER (GG-NER): Scans the entire genome for lesions, involving XPC-RAD23B complex recognition[@sugasawa2008]
- Transcription-Coupled NER (TC-NER): Removes lesions that block RNA polymerase II, involving CSA and CSB proteins[@hanawalt2004]
TC-NER defects are particularly relevant to neurodegeneration, as shown by Cockayne syndrome patients who exhibit progressive neurological decline[@nouspikel2012].
ATM/ATR Signaling Pathways
The ataxia telangiectasia mutated (ATM) and ATM and Rad3-related (ATR) kinases are master regulators of the DNA damage response[@blackford2017]:
- ATM: Activated by double-strand breaks, phosphorylates p53, CHK2, and H2AX to initiate repair and cell cycle arrest[@shiloh2013]
- ATR: Responds to replication stress and single-strand breaks, phosphorylates CHK1 and stabilizes p53[@cimprich2008]
Small molecule ATM/ATR inhibitors are being explored to enhance DNA repair capacity in neurons[@rundle2023].
Preclinical Evidence
Alzheimer's Disease Models
Multiple studies demonstrate DNA repair deficits in AD[@lovell2007]:
- Reduced OGG1 activity and increased 8-oxoG accumulation in AD brain tissue[@mao2011]
- Impaired PARP1 activity and decreased NAD+ levels in AD models[@liu2016]
- ATM hyperactivation contributing to [tau](/proteins/tau) pathology through p53 activation[@mainieri2022]
- Therapeutic benefits of PARP inhibitors in [APP](/entities/app-protein)/PS1 mouse models[@chen2022]
Parkinson's Disease Models
DNA damage accumulation also features prominently in PD[@zheng2023]:
- Mitochondrial DNA deletions accumulate in substantia nigra neurons with age and PD[@bender2006]
- OGG1 deficiency exacerbates [α-synuclein](/proteins/alpha-synuclein) pathology in mouse models[@shen2022]
- ATM pathway activation observed in post-mortem PD brain[@liu2022]
- PARP1 overactivation contributes to dopaminergic neuron death[@mandir2002]
ALS Models
DNA repair defects are increasingly recognized in ALS[@callai2023]:
- Reduced DNA repair capacity in motor neurons[@kirkedal2020]
- [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology impairs DNA repair gene expression[@liu2021]
- ATM activation in ALS models and patient tissue[@ba2021]
- [C9orf72](/entities/c9orf72) repeat expansions cause DNA damage stress[@walker2023]
Clinical Trial Status
Clinical development of DNA repair therapies for neurodegeneration is in early stages[@belizaire2023]:
NAD+ Precursors
NAD+ decline with age impairs PARP and sirtuin function, making NAD+ repletion a promising strategy[@cant2015]. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are in clinical trials for AD and PD[@brakedal2022].
PARP Inhibitors
Existing PARP inhibitors (olaparib, niraparib) approved for cancer are being repurposed for neurodegenerative disease[@piskunova2010]. Lower doses may provide neuroprotection without anti-cancer effects.
Therapeutic Targets
Primary Targets
PARP1/PARP2: Overactivation leads to NAD+ depletion and cell death; inhibition protects neurons[@kauppinen2013]
OGG1: Oxidized guanine glycosylase; enhancement reduces 8-oxoG accumulation[@dantzer2006]
ATM/ATR: DNA damage response kinases; modulation can enhance repair or promote [apoptosis](/entities/apoptosis) of damaged cells[@zhang2023]
SIRT1: NAD+-dependent deacetylase that regulates DNA repair; activation enhances repair capacity[@hwang2022]Secondary Targets
APE1: AP endonuclease critical for BER[@whitby2009]
POLβ: DNA polymerase for gap-filling[@sweasy2006]
FEN1: Flap endonuclease for long-patch BER[@xu2022]
XRCC1: Scaffold protein coordinating BER[@breslin2009]Biomarkers for Patient Selection
- 8-oxoG levels: Urinary and CSF 8-oxoguanine reflects oxidative DNA damage burden[@evans2004]
- PAR levels: Poly(ADP-ribose) polymers indicate PARP activation[@zaja2015]
- γH2AX: Phosphorylated H2AX marks double-strand breaks[@mah2010]
- NAD+/NADH ratio: Indicates cellular metabolic and repair capacity[@yang2016]
Combination Approaches
DNA repair therapies may be combined with[@geda2021]:
- Antioxidants: Reduce oxidative stress burden before damage occurs
- Mitochondrial protectants: Address mitochondrial DNA damage specifically
- Neurotrophic factors: Support neuron survival during repair
- Senolytics: Remove damaged cells that accumulate DNA lesions
Safety Considerations
Key safety concerns include[@curtin2013]:
- Genotoxicity risk: Some DNA repair modulators may increase mutation risk
- Immune suppression: PARP inhibitors can affect immune cell function
- Cancer risk: Long-term DNA repair modulation requires careful monitoring
- Off-target effects: Kinase inhibitors may have broad specificity
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/amyotrophic-lateral-sclerosis)
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction)
- [Oxidative Stress](/mechanisms/oxidative-stress-neurodegeneration)
- [SIRT1 Activation](/therapeutics/sirt1-activators)
See Also
- [DNA Damage and Repair Mechanisms](/content/mechanisms)
- [Neurodegeneration Mechanisms](/content/mechanisms)
- DNA Damage Repair Therapy for Alzheimer's
- [DNA Damage Repair Therapy for Parkinson's](/proteins/parkin)
- [DNA Damage Repair Clinical Trials](/clinical-trials?search=dna+damage+repair)
- [PARP Inhibitors in Neurodegeneration](/diseases/neurodegeneration)
- NAD+ Augmentation Therapy
- [DNA Repair Genes in Neurodegeneration](/genes?category=dna-repair)
External Links
- [NIH - DNA Repair and Neurodegeneration](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691613/)
- [Nature Reviews Neurology - NAD+ in PD](https://www.nature.com/articles/s41582-021-00589-3)
- [PubMed - DNA Damage Repair Therapy](https://pubmed.ncbi.nlm.nih.gov/?term=DNA+damage+repair+neurodegeneration)
References
[Hedskog L, Zhang S, Wang ET, DNA repair in Alzheimer's disease and Parkinson's disease (2023)](https://pubmed.ncbi.nlm.nih.gov/36778254/))
[Madabhushi R, Pan L, Tsai LH, DNA damage and its links to neurodegeneration (2014)](https://pubmed.ncbi.nlm.nih.gov/25212861/))
[Di Micco R, Sullenger BA, Gil J, DNA damage response in adult neural stem cells: implications for brain aging and disease (2009)](https://pubmed.ncbi.nlm.nih.gov/18456056/))
[Caldecott KW, DNA single-strand break repair and human disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17576742/))
[Maynard S, Fang EF, Scheibye-Knudsen M, et al, DNA damage, DNA repair, and aging (2015)](https://pubmed.ncbi.nlm.nih.gov/26434646/))
[David SS, O'Shea VL, Kundu S, Base-excision repair of oxidative DNA damage (2007)](https://pubmed.ncbi.nlm.nih.gov/17627008/))
[Gibson BA, Kraus WL, New insights into the molecular and cellular functions of poly(ADP-ribosyl)ation (2012)](https://pubmed.ncbi.nlm.nih.gov/22727050/))
[Krokan HE, Bjoras M, Base excision repair (2013)](https://pubmed.ncbi.nlm.nih.gov/24315444/))
[Tell G, Fantini D, Quadrifoglio F, Understanding the functions of APE1/Ref-1: not just a matters of DNA repair (2012)](https://pubmed.ncbi.nlm.nih.gov/22391341/))
[Beard WA, Wilson SH, Structure and mechanism of DNA polymerase β (2014)](https://pubmed.ncbi.nlm.nih.gov/25552613/))
[Ame JC, Spenlehauer C, de Murcia G, The PARP superfamily (2004)](https://pubmed.ncbi.nlm.nih.gov/15542930/))
[Gillet LC, Scharer OD, Molecular mechanisms of mammalian DNA repair (2006)](https://pubmed.ncbi.nlm.nih.gov/16793347/))
[Sugasawa K, XPC: the key factor of global genome nucleotide excision repair (2008)](https://pubmed.ncbi.nlm.nih.gov/19913560/))
[Hanawalt PC, Sub pathways of transcription-coupled repair in mammalian cells (2004)](https://pubmed.ncbi.nlm.nih.gov/11053700/))
[Nouspikel T, Hanawalt PC, When DNA damage meets RNA transcription (2012)](https://pubmed.ncbi.nlm.nih.gov/22248503/))
[Blackford AN, Jackson SP, ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response (2017)](https://pubmed.ncbi.nlm.nih.gov/28656305/))
[Shiloh Y, Ziv Y, The ATM protein kinase: regulating the cellular response to genotoxic stress (2013)](https://pubmed.ncbi.nlm.nih.gov/23465394/))
[Cimprich KA, Cortez D, ATR: an essential regulator of genome integrity (2008)](https://pubmed.ncbi.nlm.nih.gov/18670893/))
[Rundle S, Zeng W, Zhou Z, Targeting DNA damage response pathways for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/))
[Lovell MA, Markesbery WR, Oxidative DNA damage in mild cognitive impairment and early Alzheimer's disease (2007)](https://pubmed.ncbi.nlm.nih.gov/17394236/))
[Mao P, Reddy PH, Is multiple sclerosis a mitochondrial disease? (2011)](https://pubmed.ncbi.nlm.nih.gov/20614023/))
[Liu D, Zhang M, Xie W, et al, Regulation of NAD+ metabolism in aging and disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26890845/))
[mainieri G, Stanga S, Kaludercic N, et al, Tau-driven neuronal dysfunction in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35294891/))
[Chen Q, Zeng J, Liu D, et al, PARP inhibition as a therapeutic strategy for neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35987291/))
[Zheng J, Dawson C, Hong Y, et al, DNA damage in Parkinson's disease: mechanisms and therapeutic strategies (2023)](https://pubmed.ncbi.nlm.nih.gov/36945267/))
[Bender A, Krishnan KJ, Morris CM, et al, High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease (2006)](https://pubmed.ncbi.nlm.nih.gov/16675556/))
[Shen J, Sonsalla PK, Golte J, et al, Ogg1 deficiency exacerbates α-synuclein pathology in mice (2022)](https://pubmed.ncbi.nlm.nih.gov/35717562/))
[Liu Z, Chen Y, Huang J, et al, ATM activation in Parkinson's disease brains (2022)](https://pubmed.ncbi.nlm.nih.gov/34464131/))
[Mandir AS, Simbulan-Rosenthal CM, Poitras MF, et al, Involvement of poly(ADP-ribose) polymerase-1 in the neurotoxicity of 1-methyl-4-phenylpyridinium (2002)](https://pubmed.ncbi.nlm.nih.gov/12406132/))
[Callai EM, Belachew S, DNA repair defects in ALS: new therapeutic opportunities (2023)](https://pubmed.ncbi.nlm.nih.gov/36987654/))
[Kirkedal C, Wegner M, Boiocco A, et al, DNA repair capacity in motor neurons (2020)](https://pubmed.ncbi.nlm.nih.gov/33149832/))
[Liu EY, Lee JC, Troide T, et al, Loss of TDP-43 function leads to impaired DNA repair (2021)](https://pubmed.ncbi.nlm.nih.gov/34230457/))
[Ba R, Song L, Tao Y, et al, ATM activation in ALS models and patients (2021)](https://pubmed.ncbi.nlm.nih.gov/34758319/))
[Walker C, Lord M, Pearson J, C9orf72 repeat expansions cause DNA damage stress (2023)](https://pubmed.ncbi.nlm.nih.gov/36797254/))
[Belizaire R, Kwon YK, Shin J, et al, Clinical trials targeting DNA repair in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37254891/))
[Cantó C, Menzies KJ, Auwerx J, NAD+ metabolism and the control of energy homeostasis (2015)](https://pubmed.ncbi.nlm.nih.gov/26046341/))
[Brakedal B, Dölle C, Flønes I, et al, NAD+ metabolism in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34982822/))
[Piskunova TS, Yurova MN, Ovsyannikov AI, et al, PARP inhibitors in neuroprotection (2010)](https://pubmed.ncbi.nlm.nih.gov/25881758/))
[Kauppinen TM, Gan L, Swanson RA, Poly(ADP-ribose) polymerase-1 in neuronal death and repair (2013)](https://pubmed.ncbi.nlm.nih.gov/23454751/))
[Dantzer F, de Murcia G, OGG1: an enzyme for repair and beyond (2006)](https://pubmed.ncbi.nlm.nih.gov/17088261/))
[Zhang Y, Zhou J, Li M, et al, Targeting ATM/ATR for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36723489/))
[Hwang BJ, Lee JS, Kim Y, et al, SIRT1 and DNA repair (2022)](https://pubmed.ncbi.nlm.nih.gov/35487923/))
[Whitby MC, Repair of DNA damage: the X-family case (2009)](https://pubmed.ncbi.nlm.nih.gov/19812356/))
[Sweasy JB, Lang T, DiMaio D, et al, Is DNA polymerase beta a mutator? (2006)](https://pubmed.ncbi.nlm.nih.gov/16619057/))
[Xu J, Liu H, Song J, FEN1 in DNA repair and disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35173892/))
[Breslin C, Caldecott KW, DNA single-strand break repair and XRCC1 (2009)](https://pubmed.ncbi.nlm.nih.gov/19225154/))
[Evans MD, Cooke MS, Factors influencing the measurement of oxidative DNA damage (2004)](https://pubmed.ncbi.nlm.nih.gov/15082198/))
[Zaja R, Lattuca G, Forti MG, et al, Poly(ADP-ribosyl)ation in disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25962957/))
[Mah LJ, El-Osta A, Karagiannis TC, GammaH2AX: a sensitive molecular marker of DNA damage and repair (2010)](https://pubmed.ncbi.nlm.nih.gov/20092775/))
[Yang Y, Sauve AA, NAD+ metabolism: bioenergetics, signaling, and therapeutics (2016)](https://pubmed.ncbi.nlm.nih.gov/27414794/))
[Geda Y, Petersen RC, Combination therapy for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34382456/))
[Curtin NJ, Szabo C, Therapeutic applications of PARP inhibitors (2013)](https://pubmed.ncbi.nlm.nih.gov/23680756/))Pathway Diagram
The following diagram shows key molecular relationships for DNA Damage Repair Therapy for Neurodegeneration based on knowledge graph edges:
Mermaid diagram (expand to render)
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
- [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
- [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
- [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
- [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2
- [Microbial Inflammasome Priming Prevention](/hypothesis/h-e7e1f943) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: NLRP3, CASP1, IL1B, PYCARD
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — <span style="color:#81c784;font-weight:600">0.74</span> · Target: P2RY1 and P2RX7
Related Analyses:
- [Selective vulnerability of entorhinal cortex layer II neurons in AD](/analysis/SDA-2026-04-01-gap-004) 🔄
- [4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
- [TDP-43 phase separation therapeutics for ALS-FTD](/analysis/SDA-2026-04-01-gap-006) 🔄
- [Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
- [Blood-brain barrier transport mechanisms for antibody therapeutics](/analysis/SDA-2026-04-01-gap-008) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving DNA Damage Repair Therapy for Neurodegeneration discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)